201 related articles for article (PubMed ID: 16873292)
1. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
Berois N; Blanc E; Ripoche H; Mergui X; Trajtenberg F; Cantais S; Barrois M; Dessen P; Kågedal B; Bénard J; Osinaga E; Raguénez G
Clin Chem; 2006 Sep; 52(9):1701-12. PubMed ID: 16873292
[TBL] [Abstract][Full Text] [Related]
2. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
4. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature.
Scaruffi P; Morandi F; Gallo F; Stigliani S; Parodi S; Moretti S; Bonassi S; Fardin P; Garaventa A; Zanazzo G; Pistoia V; Tonini GP; Corrias MV
Pediatr Blood Cancer; 2012 Jul; 59(1):44-51. PubMed ID: 21994039
[TBL] [Abstract][Full Text] [Related]
6. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
[TBL] [Abstract][Full Text] [Related]
7. Presence of differentiating neuroblasts in bone marrow is a favorable prognostic factor for bone marrow metastatic neuroblastoma at diagnosis.
Park SH; Kim S; Park CJ; Jang S; Chi HS; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2013 Mar; 33(2):89-96. PubMed ID: 23483759
[TBL] [Abstract][Full Text] [Related]
8. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
[TBL] [Abstract][Full Text] [Related]
11. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
12. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
[TBL] [Abstract][Full Text] [Related]
13. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of the determination of bone marrow lesion in patients with neuroblastoma based on the gene PHOX2B and TH expression].
Druĭ AE; Shorikov EV; Tsaur GA; Popov AM; Tuponogov SN; Savel'ëv LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2014; 60(2):57-62. PubMed ID: 24919263
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bone marrow as a metastatic site of human neuroblastoma.
Morandi F; Corrias MV; Pistoia V
Ann N Y Acad Sci; 2015 Jan; 1335():23-31. PubMed ID: 25315505
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
[TBL] [Abstract][Full Text] [Related]
19. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
20. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
